Do analysts recommend PLRZ or CGTX?

Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 220.51%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, PLRZ or CGTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A

Is PLRZ or CGTX more profitable?

Polyrizon's return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Cognition Therapeutics N/A -50.17% -40.22%

Do analysts prefer PLRZ or ICCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, PLRZ or ICCC?

ImmuCell has higher revenue and earnings than Polyrizon. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A ImmuCell $27.64M 3.27 -$1.04M $0.08 124.38

Do analysts prefer PLRZ or MNOV?

MediciNova has a consensus target price of $7.75, indicating a potential upside of 133.43%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has preferable earnings & valuation, PLRZ or MNOV?

Polyrizon has higher earnings, but lower revenue than MediciNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A MediciNova $410K 398.56 -$12M -$0.21 N/A

Do analysts prefer NTRB or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, NTRB or PLRZ?

Polyrizon has lower revenue, but higher earnings than Nutriband. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nutriband $2.04M 48.46 -$8.23M -$0.53 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is NTRB or PLRZ more profitable?

Polyrizon has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Polyrizon's return on equity of 0.00% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -430.35% -109.07% -95.54% Polyrizon N/A N/A N/A

Which has preferable valuation & earnings, VRCA or PLRZ?

Polyrizon has lower revenue, but higher earnings than Verrica Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verrica Pharmaceuticals $35.58M 2.15 -$17.89M -$1.67 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Polyrizon (PLRZ) Competitors

$10.99 -0.04 (-0.36%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.66 -0.33 (-2.97%)

As of 09/18/2026 07:30 PM Eastern

Compare

PLRZ vs. CGTX, ICCC, MNOV, NTRB, and VRCA

Should you buy Polyrizon stock or one of its competitors? Polyrizon's main competitors and comparable companies include Cognition Therapeutics (CGTX), ImmuCell (ICCC), MediciNova (MNOV), Nutriband (NTRB), and Verrica Pharmaceuticals (VRCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Polyrizon compare to Cognition Therapeutics?

Polyrizon (NASDAQ:PLRZ) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 220.51%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Polyrizon has a beta of -1.39, indicating that its share price is 239% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

In the previous week, Cognition Therapeutics had 1 more articles in the media than Polyrizon. MarketBeat recorded 1 mentions for Cognition Therapeutics and 0 mentions for Polyrizon. Cognition Therapeutics' average media sentiment score of 1.34 beat Polyrizon's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Polyrizon	Neutral
Cognition Therapeutics	Positive

Polyrizon's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Cognition Therapeutics	N/A	-50.17%	-40.22%

43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cognition Therapeutics beats Polyrizon on 8 of the 11 factors compared between the two stocks.

How does Polyrizon compare to ImmuCell?

Polyrizon (NASDAQ:PLRZ) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

13.5% of ImmuCell shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ImmuCell has higher revenue and earnings than Polyrizon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
ImmuCell	$27.64M	3.27	-$1.04M	$0.08	124.38

ImmuCell has a net margin of 2.57% compared to Polyrizon's net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Polyrizon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
ImmuCell	2.57%	2.69%	1.76%

Polyrizon has a beta of -1.39, indicating that its share price is 239% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, ImmuCell had 1 more articles in the media than Polyrizon. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score.

Company	Overall Sentiment
Polyrizon	Neutral
ImmuCell	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ImmuCell beats Polyrizon on 10 of the 10 factors compared between the two stocks.

How does Polyrizon compare to MediciNova?

Polyrizon (NASDAQ:PLRZ) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Polyrizon has a beta of -1.39, indicating that its stock price is 239% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Polyrizon has higher earnings, but lower revenue than MediciNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
MediciNova	$410K	398.56	-$12M	-$0.21	N/A

9.9% of MediciNova shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Polyrizon has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. Polyrizon's return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
MediciNova	-1,168.70%	-26.51%	-24.39%

MediciNova has a consensus target price of $7.75, indicating a potential upside of 133.43%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, MediciNova had 7 more articles in the media than Polyrizon. MarketBeat recorded 7 mentions for MediciNova and 0 mentions for Polyrizon. MediciNova's average media sentiment score of 0.66 beat Polyrizon's score of 0.00 indicating that MediciNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Polyrizon	Neutral
MediciNova	Positive

Summary

MediciNova beats Polyrizon on 10 of the 14 factors compared between the two stocks.

How does Polyrizon compare to Nutriband?

Nutriband (NASDAQ:NTRB) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Nutriband's average media sentiment score of 0.00 equaled Polyrizon'saverage media sentiment score.

Company	Overall Sentiment
Nutriband	Neutral
Polyrizon	Neutral

Polyrizon has lower revenue, but higher earnings than Nutriband.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	48.46	-$8.23M	-$0.53	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Polyrizon has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Polyrizon's return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Polyrizon	N/A	N/A	N/A

19.7% of Nutriband shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nutriband has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.39, meaning that its stock price is 239% less volatile than the broader market.

Summary

Nutriband beats Polyrizon on 5 of the 9 factors compared between the two stocks.

How does Polyrizon compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Polyrizon has lower revenue, but higher earnings than Verrica Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.15	-$17.89M	-$1.67	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Polyrizon. MarketBeat recorded 1 mentions for Verrica Pharmaceuticals and 0 mentions for Polyrizon. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Polyrizon's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Positive
Polyrizon	Neutral

Polyrizon has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Polyrizon's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Polyrizon	N/A	N/A	N/A

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.39, indicating that its share price is 239% less volatile than the broader market.

Verrica Pharmaceuticals presently has a consensus target price of $12.67, suggesting a potential upside of 184.64%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Verrica Pharmaceuticals is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Verrica Pharmaceuticals beats Polyrizon on 9 of the 13 factors compared between the two stocks.

Get Polyrizon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRZ vs. The Competition

Export

Metric	Polyrizon	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.51M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	N/A	797.25	275.49	25.40
Price / Sales	N/A	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	0.84	10.53	10.46	6.33
Net Income	-$3.34M	$2.82B	$3.49B	$358.33M
7 Day Performance	-0.36%	1.69%	0.59%	1.12%
1 Month Performance	4.77%	0.24%	-1.74%	-2.39%
1 Year Performance	63.54%	3.95%	18.13%	5.35%

Polyrizon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRZ Polyrizon	0.6653 of 5 stars	$10.99 -0.4%	N/A	+63.5%	$23.51M	N/A	N/A	1	Analyst Upgrade
CGTX Cognition Therapeutics	2.3167 of 5 stars	$0.98 +0.3%	$3.33 +239.2%	-25.7%	$93.45M	N/A	N/A	20	News Coverage Positive News
ICCC ImmuCell	0.4695 of 5 stars	$9.85 -0.6%	N/A	+66.9%	$89.44M	$27.64M	123.14	70	News Coverage Positive News
MNOV MediciNova	2.4719 of 5 stars	$1.81 +4.0%	$8.33 +360.4%	+161.4%	$89.09M	$410K	N/A	10	News Coverage Analyst Upgrade Gap Down
NTRB Nutriband	0.3387 of 5 stars	$6.96 +14.5%	N/A	+12.6%	$84.63M	$2.04M	N/A	10	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRZ) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polyrizon (PLRZ) Competitors

PLRZ vs. CGTX, ICCC, MNOV, NTRB, and VRCA

How does Polyrizon compare to Cognition Therapeutics?

Summary

How does Polyrizon compare to ImmuCell?

Summary

How does Polyrizon compare to MediciNova?

Summary

How does Polyrizon compare to Nutriband?

Summary

How does Polyrizon compare to Verrica Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polyrizon (PLRZ) Competitors

PLRZ vs. CGTX, ICCC, MNOV, NTRB, and VRCA

How does Polyrizon compare to Cognition Therapeutics?

Do analysts recommend PLRZ or CGTX?

Which has more volatility & risk, PLRZ or CGTX?

Which has preferable earnings and valuation, PLRZ or CGTX?

Does the media prefer PLRZ or CGTX?

Is PLRZ or CGTX more profitable?

Do institutionals & insiders have more ownership in PLRZ or CGTX?

Summary

How does Polyrizon compare to ImmuCell?

Do insiders & institutionals believe in PLRZ or ICCC?

Which has better earnings & valuation, PLRZ or ICCC?

Is PLRZ or ICCC more profitable?

Which has more volatility and risk, PLRZ or ICCC?

Does the media prefer PLRZ or ICCC?

Do analysts prefer PLRZ or ICCC?

Summary

How does Polyrizon compare to MediciNova?

Which has more volatility and risk, PLRZ or MNOV?

Which has preferable earnings & valuation, PLRZ or MNOV?

Do institutionals and insiders have more ownership in PLRZ or MNOV?

Is PLRZ or MNOV more profitable?

Do analysts prefer PLRZ or MNOV?

Does the media refer more to PLRZ or MNOV?

Summary

How does Polyrizon compare to Nutriband?

Do analysts prefer NTRB or PLRZ?

Does the media prefer NTRB or PLRZ?

Which has preferable valuation and earnings, NTRB or PLRZ?

Is NTRB or PLRZ more profitable?

Do institutionals & insiders believe in NTRB or PLRZ?

Which has more volatility and risk, NTRB or PLRZ?

Summary

How does Polyrizon compare to Verrica Pharmaceuticals?

Which has preferable valuation & earnings, VRCA or PLRZ?

Does the media prefer VRCA or PLRZ?

Is VRCA or PLRZ more profitable?

Which has more risk and volatility, VRCA or PLRZ?

Do analysts prefer VRCA or PLRZ?

Do institutionals & insiders have more ownership in VRCA or PLRZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools